New osteoporosis treatment

New data released in Europe shows the benefit of Protelos(R) in a wide range of osteoporosis patients, irrespective of disease severity.

Protelos is a new anti-osteoporosis treatment which both increases bone formation and decreases bone resorption.

Supporting data shows sustained, five year efficacy against vertebral and non-vertebral fractures, including hip fractures.

The five year results- which included testing in Australia- revealed a 24% reduction in vertebral fracture and 15% reduction in non-vertebral fractures. There was a 43% reduction of the risk of hip fracture in women who had a higher risk of fractures (74 years and older with a low lumbar and femoral neck bone mineral density T-score).

“These robust results show Protelos’ sustained quality of life benefits… and it is the first anti-osteoporotic treatment to show this benefit for this patient group,” says lead investigator Professor Roux from Hopital Cochin, Paris.

Protelos is licensed in Europe for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fractures in patients with or without a previous history of fractures.